The extracellular matrix in cancer progression: Role of hyalectan proteoglycans and ADAMTS enzymes

Cancer Letters

Volumn 385, Issue , 2017, Pages 55-64

  Binder, Marley J ^a   McCoombe, Scott ^a   Williams, Elizabeth D ^b   McCulloch, Daniel R ^a   Ward, Alister C ^a  

^a DEAKIN UNIVERSITY   (Australia)

^b QUEENSLAND UNIVERSITY OF TECHNOLOGY   (Australia)

Author keywords

ADAMTS; Cancer; Extracellular matrix; Hyalectan; Versican

Indexed keywords

ADAMTS1 PROTEIN; CELL SURFACE RECEPTOR; EPIDERMAL GROWTH FACTOR RECEPTOR; GLYCOSAMINOGLYCAN; HERMES ANTIGEN; HYALECTAN PROTEOGLYCAN; HYPOXIA INDUCIBLE FACTOR 1; INITIATION FACTOR 4E BINDING PROTEIN; MITOGEN ACTIVATED PROTEIN KINASE 3; PROTEOGLYCAN; S6 KINASE; TISSUE INHIBITOR OF METALLOPROTEINASE; TRANSFORMING GROWTH FACTOR BETA; UNCLASSIFIED DRUG; VASCULOTROPIN A; VERSICAN; VON WILLEBRAND FACTOR; ADAMTS PROTEIN; HYALECTIN;

AMINO TERMINAL SEQUENCE; BINDING SITE; CANCER GROWTH; CANCER INHIBITION; CARBOXY TERMINAL SEQUENCE; CARCINOGENESIS; CELL METABOLISM; DISEASE ASSOCIATION; DISEASE FREE SURVIVAL; ENZYME ACTIVATION; ENZYME GLYCOSYLATION; EXTRACELLULAR MATRIX; HUMAN; INFLAMMATION; METASTASIS; NONHUMAN; PRIORITY JOURNAL; PROTEIN BINDING; PROTEIN CLEAVAGE; PROTEIN EXPRESSION; PROTEIN INTERACTION; SHORT SURVEY; SIGNAL TRANSDUCTION; TUMOR VASCULARIZATION; ANIMAL; DISEASE COURSE; ENZYMOLOGY; METABOLISM; NEOPLASM; PATHOLOGY; TUMOR MICROENVIRONMENT;

ADAMTS PROTEINS; ANIMALS; DISEASE PROGRESSION; EXTRACELLULAR MATRIX; HUMANS; HYALECTINS; NEOPLASMS; SIGNAL TRANSDUCTION; TUMOR MICROENVIRONMENT;

EID: 84996548962     PISSN: 03043835     EISSN: 18727980     Source Type: Journal    
DOI: 10.1016/j.canlet.2016.11.001     Document Type: Review

References (195)

1. [1] Frantz, C., Stewart, K.M., Weaver, V.M., The extracellular matrix at a glance. J. Cell Sci. 123 (2010), 4195–4200.
2. [2] Suhovskih, A.V., Mostovich, L.A., Kunin, I.S., Boboev, M.M., Nepomnyashchikh, G.I., Aidagulova, S.V., et al. Proteoglycan expression in normal human prostate tissue and prostate cancer. ISRN Oncol., 2013, 2013, 680136.
3. [3] Blehm, B.H., Jiang, N., Kotobuki, Y., Tanner, K., Deconstructing the role of the ECM microenvironment on drug efficacy targeting MAPK signaling in a pre-clinical platform for cutaneous melanoma. Biomaterials 56 (2015), 129–139.
4. [4] Fullar, A., Dudas, J., Olah, L., Hollosi, P., Papp, Z., Sobel, G., et al. Remodeling of extracellular matrix by normal and tumor-associated fibroblasts promotes cervical cancer progression. BMC Cancer, 15, 2015, 256.
5. [5] de Kruijf, E.M., van Nes, J.G., van de Velde, C.J., Putter, H., Smit, V.T., Liefers, G.J., et al. Tumor-stroma ratio in the primary tumor is a prognostic factor in early breast cancer patients, especially in triple-negative carcinoma patients. Breast Cancer Res. Treat. 125 (2011), 687–696.
6. [6] Suhovskih, A.V., Aidagulova, S.V., Kashuba, V.I., Grigorieva, E.V., Proteoglycans as potential microenvironmental biomarkers for colon cancer. Cell Tissue Res. 361 (2015), 833–844.
7. [7] Januchowski, R., Zawierucha, P., Rucinski, M., Nowicki, M., Zabel, M., Extracellular matrix proteins expression profiling in chemoresistant variants of the A2780 ovarian cancer cell line. Biomed. Res. Int., 2014, 2014, 365867.
8. [8] Lamouille, S., Xu, J., Derynck, R., Molecular mechanisms of epithelial-mesenchymal transition. Nat. Rev. Mol. Cell Biol. 15 (2014), 178–196.
9. [9] Bosman, F.T., Stamenkovic, I., Functional structure and composition of the extracellular matrix. J. Pathol. 200 (2003), 423–428.
10. [10] Theocharis, A.D., Skandalis, S.S., Tzanakakis, G.N., Karamanos, N.K., Proteoglycans in health and disease: novel roles for proteoglycans in malignancy and their pharmacological targeting. FEBS J. 277 (2010), 3904–3923.
11. [11] Yip, G.W., Smollich, M., Gotte, M., Therapeutic value of glycosaminoglycans in cancer. Mol. Cancer Ther. 5 (2006), 2139–2148.
12. [12] Knudson, W., Knudson, C.B., Assembly of a chondrocyte-like pericellular matrix on non-chondrogenic cells. Role of the cell surface hyaluronan receptors in the assembly of a pericellular matrix. J. Cell Sci. 99:Pt 2 (1991), 227–235.
13. [13] Fotia, C., Messina, G.M., Marletta, G., Baldini, N., Ciapetti, G., Hyaluronan-based pericellular matrix: substrate electrostatic charges and early cell adhesion events. Eur. Cell Mater. 26 (2013), 133–149 discussion 149.
14. [14] Lee, G.M., Johnstone, B., Jacobson, K., Caterson, B., The dynamic structure of the pericellular matrix on living cells. J. Cell Biol. 123 (1993), 1899–1907.
15. [15] Zimmerman, E., Geiger, B., Addadi, L., Initial stages of cell-matrix adhesion can be mediated and modulated by cell-surface hyaluronan. Biophys. J. 82 (2002), 1848–1857.
16. [16] Nijenhuis, N., Mizuno, D., Spaan, J.A., Schmidt, C.F., High-resolution microrheology in the pericellular matrix of prostate cancer cells. J. R. Soc. Interface 9 (2012), 1733–1744.
17. [17] Knudson, C.B., Knudson, W., Hyaluronan-binding proteins in development, tissue homeostasis, and disease. FASEB J. 7 (1993), 1233–1241.
18. [18] Avnet, S., Cortini, M., Role of pericellular matrix in the regulation of cancer stemness. Stem Cell Rev. 12 (2016), 464–475.
19. [19] Lin, S.L., Chang, D., Chiang, A., Ying, S.Y., Androgen receptor regulates CD168 expression and signaling in prostate cancer. Carcinogenesis 29 (2008), 282–290.
20. [20] Toole, B.P., Hyaluronan: from extracellular glue to pericellular cue. Nat. Rev. Cancer 4 (2004), 528–539.
21. [21] Day, A.J., Prestwich, G.D., Hyaluronan-binding proteins: tying up the giant. J. Biol. Chem. 277 (2002), 4585–4588.
22. [22] Evanko, S.P., Tammi, M.I., Tammi, R.H., Wight, T.N., Hyaluronan-dependent pericellular matrix. Adv. Drug Deliv. Rev. 59 (2007), 1351–1365.
23. [23] Weigelt, B., Downward, J., Genomic determinants of PI3K pathway inhibitor response in cancer. Front. Oncol., 2, 2012, 109.
24. [24] Stern, R., Hyaluronan metabolism: a major paradox in cancer biology. Pathol. Biol. (Paris) 53 (2005), 372–382.
25. [25] Petrey, A.C., de la Motte, C.A., Hyaluronan, a crucial regulator of inflammation. Front. Immunol., 5, 2014, 101.
26. [26] Wight, T.N., Versican: a versatile extracellular matrix proteoglycan in cell biology. Curr. Opin. Cell Biol. 14 (2002), 617–623.
27. [27] Wight, T.N., Kinsella, M.G., Evanko, S.P., Potter-Perigo, S., Merrilees, M.J., Versican and the regulation of cell phenotype in disease. Biochim. Biophys. Acta 1840 (2014), 2441–2451.
28. [28] Shinomura, T., Zako, M., Ito, K., Ujita, M., Kimata, K., The gene structure and organization of mouse PG-M, a large chondroitin sulfate proteoglycan. Genomic background for the generation of multiple PG-M transcripts. J. Biol. Chem. 270 (1995), 10328–10333.
29. [29] Dours-Zimmermann, M.T., Zimmermann, D.R., A novel glycosaminoglycan attachment domain identified in two alternative splice variants of human versican. J. Biol. Chem. 269 (1994), 32992–32998.
30. [30] Wu, Y.J., La Pierre, D.P., Wu, J., Yee, A.J., Yang, B.B., The interaction of versican with its binding partners. Cell Res. 15 (2005), 483–494.
31. [31] Ito, K., Shinomura, T., Zako, M., Ujita, M., Kimata, K., Multiple forms of mouse PG-M, a large chondroitin sulfate proteoglycan generated by alternative splicing. J. Biol. Chem. 270 (1995), 958–965.
32. [32] LeBaron, R.G., Zimmermann, D.R., Ruoslahti, E., Hyaluronate binding properties of versican. J. Biol. Chem. 267 (1992), 10003–10010.
33. [33] Zimmermann, D.R., Ruoslahti, E., Multiple domains of the large fibroblast proteoglycan, versican. EMBO J. 8 (1989), 2975–2981.
34. [34] Zhang, C., Yang, Y., The G3 domain of versican enhances cell proliferation via epidermial growth factor-like motifs. J. Biol. Chem. 273 (1998), 21342–21351.
35. [35] Naso, M.F., Zimmermann, D.R., Iozzo, R.V., Characterization of the complete genomic structure of the human versican gene and functional analysis of its promoter. J. Biol. Chem. 269 (1994), 32999–33008.
36. [36] Kischel, P., Waltregny, D., Dumont, B., Turtoi, A., Greffe, Y., Kirsch, S., et al. Versican overexpression in human breast cancer lesions: known and new isoforms for stromal tumor targeting. Int. J. Cancer 126 (2010), 640–650.
37. [37] Cattaruzza, S., Schiappacassi, M., Ljungberg-Rose, A., Spessotto, P., Perissinotto, D., Morgelin, M., et al. Distribution of PG-M/versican variants in human tissues and de novo expression of isoform V3 upon endothelial cell activation, migration, and neoangiogenesis in vitro. J. Biol. Chem. 277 (2002), 47626–47635.
38. [38] Dours-Zimmermann, M.T., Maurer, K., Rauch, U., Stoffel, W., Fassler, R., Zimmermann, D.R., Versican V2 assembles the extracellular matrix surrounding the nodes of ranvier in the CNS. J. Neurosci. 29 (2009), 7731–7742.
39. [39] Bode-Lesniewska, B., Dours-Zimmermann, M.T., Odermatt, B.F., Briner, J., Heitz, P.U., Zimmermann, D.R., Distribution of the large aggregating proteoglycan versican in adult human tissues. J. Histochem Cytochem 44 (1996), 303–312.
40. [40] Skandalis, S.S., Theocharis, A.D., Vynios, D.H., Papageorgakopoulou, N., Hjerpe, A., Karamanos, N.K., et al. Cartilage aggrecan undergoes significant compositional and structural alterations during laryngeal cancer. Biochim. Biophys. Acta 1760 (2006), 1046–1053.
41. [41] Haller, J.M., Swearingen, C.A., Partridge, D., McFadden, M., Thirunavukkarasu, K., Higgins, T.F., Intraarticular matrix metalloproteinases and aggrecan degradation are elevated after articular fracture. Clin. Orthop. Relat. Res. 473 (2015), 3280–3288.
42. [42] Tourville, T.W., Poynter, M.E., DeSarno, M.J., Struglics, A., Beynnon, B.D., The relationship between synovial fluid ARGS-aggrecan fragments, cytokines, MMPs and TIMPs following acute ACL injury: a cross-sectional study. J. Orthop. Res. 33 (2015), 1796–1803.
43. [43] Dudhia, J., Aggrecan, aging and assembly in articular cartilage. Cell Mol. Life Sci. 62 (2005), 2241–2256.
44. [44] Aspberg, A., The different roles of aggrecan interaction domains. J. Histochem Cytochem 60 (2012), 987–996.
45. [45] Heinegard, D., Saxne, T., The role of the cartilage matrix in osteoarthritis. Nat. Rev. Rheumatol. 7 (2011), 50–56.
46. [46] Rauch, U., Karthikeyan, L., Maurel, P., Margolis, R.U., Margolis, R.K., Cloning and primary structure of neurocan, a developmentally regulated, aggregating chondroitin sulfate proteoglycan of brain. J. Biol. Chem. 267 (1992), 19536–19547.
47. [47] Prange, C.K., Pennacchio, L.A., Lieuallen, K., Fan, W., Lennon, G.G., Characterization of the human neurocan gene, CSPG31. Gene 221 (1998), 199–205.
48. [48] Friedlander, D.R., Milev, P., Karthikeyan, L., Margolis, R.K., Margolis, R.U., Grumet, M., The neuronal chondroitin sulfate proteoglycan neurocan binds to the neural cell adhesion molecules Ng-CAM/L1/NILE and N-CAM, and inhibits neuronal adhesion and neurite outgrowth. J. Cell Biol. 125 (1994), 669–680.
49. [49] Grumet, M., Flaccus, A., Margolis, R.U., Functional characterization of chondroitin sulfate proteoglycans of brain: interactions with neurons and neural cell adhesion molecules. J. Cell Biol. 120 (1993), 815–824.
50. [50] Snow, D.M., Lemmon, V., Carrino, D.A., Caplan, A.I., Silver, J., Sulfated proteoglycans in astroglial barriers inhibit neurite outgrowth in vitro. Exp. Neurol. 109 (1990), 111–130.
51. [51] Grumet, M., Milev, P., Sakurai, T., Karthikeyan, L., Bourdon, M., Margolis, R.K., et al. Interactions with tenascin and differential effects on cell adhesion of neurocan and phosphacan, two major chondroitin sulfate proteoglycans of nervous tissue. J. Biol. Chem. 269 (1994), 12142–12146.
52. [52] Milev, P., Maurel, P., Haring, M., Margolis, R.K., Margolis, R.U., TAG-1/axonin-1 is a high-affinity ligand of neurocan, phosphacan/protein-tyrosine phosphatase-zeta/beta, and N-CAM. J. Biol. Chem. 271 (1996), 15716–15723.
53. [53] Talts, U., Kuhn, U., Roos, G., Rauch, U., Modulation of extracellular matrix adhesiveness by neurocan and identification of its molecular basis. Exp. Cell Res. 259 (2000), 378–388.
54. [54] Akita, K., Toda, M., Hosoki, Y., Inoue, M., Fushiki, S., Oohira, A., et al. Heparan sulphate proteoglycans interact with neurocan and promote neurite outgrowth from cerebellar granule cells. Biochem. J. 383 (2004), 129–138.
55. [55] Hu, B., Kong, L.L., Matthews, R.T., Viapiano, M.S., The proteoglycan brevican binds to fibronectin after proteolytic cleavage and promotes glioma cell motility. J. Biol. Chem. 283 (2008), 24848–24859.
56. [56] Dwyer, C.A., Bi, W.L., Viapiano, M.S., Matthews, R.T., Brevican knockdown reduces late-stage glioma tumor aggressiveness. J. Neurooncol. 120 (2014), 63–72.
57. [57] Varga, I., Hutoczki, G., Szemcsak, C.D., Zahuczky, G., Toth, J., Adamecz, Z., et al. Brevican, neurocan, tenascin-C and versican are mainly responsible for the invasiveness of low-grade astrocytoma. Pathol. Oncol. Res. 18 (2012), 413–420.
58. [58] Jaworski, D.M., Kelly, G.M., Hockfield, S., BEHAB, a new member of the proteoglycan tandem repeat family of hyaluronan-binding proteins that is restricted to the brain. J. Cell Biol. 125 (1994), 495–509.
59. [59] Yamada, H., Watanabe, K., Shimonaka, M., Yamaguchi, Y., Molecular cloning of brevican, a novel brain proteoglycan of the aggrecan/versican family. J. Biol. Chem. 269 (1994), 10119–10126.
60. [60] Gary, S.C., Kelly, G.M., Hockfield, S., BEHAB/brevican: a brain-specific lectican implicated in gliomas and glial cell motility. Curr. Opin. Neurobiol. 8 (1998), 576–581.
61. [61] Gary, S.C., Zerillo, C.A., Chiang, V.L., Gaw, J.U., Gray, G., Hockfield, S., cDNA cloning, chromosomal localization, and expression analysis of human BEHAB/brevican, a brain specific proteoglycan regulated during cortical development and in glioma. Gene 256 (2000), 139–147.
62. [62] Gomis-Ruth, F.X., Catalytic domain architecture of metzincin metalloproteases. J. Biol. Chem. 284 (2009), 15353–15357.
63. [63] Cawston, T.E., Young, D.A., Proteinases involved in matrix turnover during cartilage and bone breakdown. Cell Tissue Res. 339 (2010), 221–235.
64. [64] McCulloch, D.R., Nelson, C.M., Dixon, L.J., Silver, D.L., Wylie, J.D., Lindner, V., et al. ADAMTS metalloproteases generate active versican fragments that regulate interdigital web regression. Dev. Cell 17 (2009), 687–698.
65. [65] Wagstaff, L., Kelwick, R., Decock, J., Edwards, D.R., The roles of ADAMTS metalloproteinases in tumorigenesis and metastasis. Front. Biosci. 16 (2011), 1861–1872.
66. [66] Stupka, N., Kintakas, C., White, J.D., Fraser, F.W., Hanciu, M., Aramaki-Hattori, N., et al. Versican processing by a disintegrin-like and metalloproteinase domain with thrombospondin-1 repeats proteinases-5 and -15 facilitates myoblast fusion. J. Biol. Chem. 288 (2013), 1907–1917.
67. [67] Apte, S.S., A disintegrin-like and metalloprotease (reprolysin-type) with thrombospondin type 1 motif (ADAMTS) superfamily: functions and mechanisms. J. Biol. Chem. 284 (2009), 31493–31497.
68. [68] Stanton, H., Melrose, J., Little, C.B., Fosang, A.J., Proteoglycan degradation by the ADAMTS family of proteinases. Biochim. Biophys. Acta 1812 (2011), 1616–1629.
69. [69] Cross, N.A., Chandrasekharan, S., Jokonya, N., Fowles, A., Hamdy, F.C., Buttle, D.J., et al. The expression and regulation of ADAMTS-1, -4, -5, -9, and -15, and TIMP-3 by TGFbeta1 in prostate cells: relevance to the accumulation of versican. Prostate 63 (2005), 269–275.
70. [70] Zhou, Z., Jing, H., Tao, Z., Choi, H., Aboulfatova, K., Moake, J., et al. Effects of naturally occurring mutations in CUB-1 domain on synthesis, stability, and activity of ADAMTS-13. Thromb. Res. 124 (2009), 323–327.
71. [71] Cao, L.B., Jones, C., Movahed, A., Low ADAMTS-13 in plavix induced thrombotic thrombocytopenic purpura. World J. Clin. Cases 1 (2013), 31–33.
72. [72] Li, W., Wu, M., Jiang, S., Ding, W., Luo, Q., Shi, J., Expression of ADAMTs-5 and TIMP-3 in the condylar cartilage of rats induced by experimentally created osteoarthritis. Arch. Oral Biol. 59 (2014), 524–529.
73. [73] Murphy, G., Tissue inhibitors of metalloproteinases. Genome Biol., 12, 2011, 233.
74. [74] Ricciardelli, C., Mayne, K., Sykes, P.J., Raymond, W.A., McCaul, K., Marshall, V.R., et al. Elevated levels of versican but not decorin predict disease progression in early-stage prostate cancer. Clin. Cancer Res. 4 (1998), 963–971.
75. [75] Ricciardelli, C., Mayne, K., Sykes, P.J., Raymond, W.A., McCaul, K., Marshall, V.R., et al. Elevated stromal chondroitin sulfate glycosaminoglycan predicts progression in early-stage prostate cancer. Clin. Cancer Res. 3 (1997), 983–992.
76. [76] Ricciardelli, C., Quinn, D.I., Raymond, W.A., McCaul, K., Sutherland, P.D., Stricker, P.D., et al. Elevated levels of peritumoral chondroitin sulfate are predictive of poor prognosis in patients treated by radical prostatectomy for early-stage prostate cancer. Cancer Res. 59 (1999), 2324–2328.
77. [77] Ricciardelli, C., Russell, D.L., Ween, M.P., Mayne, K., Suwiwat, S., Byers, S., et al. Formation of hyaluronan- and versican-rich pericellular matrix by prostate cancer cells promotes cell motility. J. Biol. Chem. 282 (2007), 10814–10825.
78. [78] Sakko, A.J., Ricciardelli, C., Mayne, K., Suwiwat, S., LeBaron, R.G., Marshall, V.R., et al. Modulation of prostate cancer cell attachment to matrix by versican. Cancer Res. 63 (2003), 4786–4791.
79. [79] Sakko, A.J., Ricciardelli, C., Mayne, K., Tilley, W.D., Lebaron, R.G., Horsfall, D.J., Versican accumulation in human prostatic fibroblast cultures is enhanced by prostate cancer cell-derived transforming growth factor beta1. Cancer Res. 61 (2001), 926–930.
80. [80] True, L.D., Hawley, S., Norwood, T.H., Braun, K.R., Evanko, S.P., Chan, C.K., et al. The accumulation of versican in the nodules of benign prostatic hyperplasia. Prostate 69 (2009), 149–158.
81. [81] Gupta, N., Khan, R., Kumar, R., Kumar, L., Sharma, A., Versican and its associated molecules: potential diagnostic markers for multiple myeloma. Clin. Chim. Acta 442 (2015), 119–124.
82. [82] Yang, W., Yee, A.J., Versican V2 isoform enhances angiogenesis by regulating endothelial cell activities and fibronectin expression. FEBS Lett. 587 (2013), 185–192.
83. [83] Du, W.W., Fang, L., Yang, W., Sheng, W., Zhang, Y., Seth, A., et al. The role of versican G3 domain in regulating breast cancer cell motility including effects on osteoblast cell growth and differentiation in vitro - evaluation towards understanding breast cancer cell bone metastasis. BMC Cancer, 12, 2012, 341.
84. [84] Desjardins, M., Xie, J., Gurler, H., Muralidhar, G.G., Sacks, J.D., Burdette, J.E., et al. Versican regulates metastasis of epithelial ovarian carcinoma cells and spheroids. J. Ovarian Res., 7, 2014, 70.
85. [85] Davidson, B., Trope, C.G., Reich, R., The role of the tumor stroma in ovarian cancer. Front. Oncol., 4, 2014, 104.
86. [86] Ghosh, S., Albitar, L., LeBaron, R., Welch, W.R., Samimi, G., Birrer, M.J., et al. Up-regulation of stromal versican expression in advanced stage serous ovarian cancer. Gynecol. Oncol. 119 (2010), 114–120.
87. [87] Kusumoto, T., Kodama, J., Seki, N., Nakamura, K., Hongo, A., Hiramatsu, Y., Clinical significance of syndecan-1 and versican expression in human epithelial ovarian cancer. Oncol. Rep. 23 (2010), 917–925.
88. [88] Voutilainen, K., Anttila, M., Sillanpaa, S., Tammi, R., Tammi, M., Saarikoski, S., et al. Versican in epithelial ovarian cancer: relation to hyaluronan, clinicopathologic factors and prognosis. Int. J. Cancer 107 (2003), 359–364.
89. [89] Paulus, W., Baur, I., Dours-Zimmermann, M.T., Zimmermann, D.R., Differential expression of versican isoforms in brain tumors. J. Neuropathol. Exp. Neurol. 55 (1996), 528–533.
90. [90] Kodama, J., Hasengaowa, Kusumoto, T., Seki, N., Matsuo, T., Nakamura, K., et al. Versican expression in human cervical cancer. Eur. J. Cancer 43 (2007), 1460–1466.
91. [91] Skandalis, S.S., Labropoulou, V.T., Ravazoula, P., Likaki-Karatza, E., Dobra, K., Kalofonos, H.P., et al. Versican but not decorin accumulation is related to malignancy in mammographically detected high density and malignant-appearing microcalcifications in non-palpable breast carcinomas. BMC Cancer, 11, 2011, 314.
92. [92] Skandalis, S.S., Kletsas, D., Kyriakopoulou, D., Stavropoulos, M., Theocharis, D.A., The greatly increased amounts of accumulated versican and decorin with specific post-translational modifications may be closely associated with the malignant phenotype of pancreatic cancer. Biochim. Biophys. Acta 1760 (2006), 1217–1225.
93. [93] Skandalis, S.S., Theocharis, A.D., Theocharis, D.A., Papadas, T., Vynios, D.H., Papageorgakopoulou, N., Matrix proteoglycans are markedly affected in advanced laryngeal squamous cell carcinoma. Biochim. Biophys. Acta 1689 (2004), 152–161.
94. [94] Labropoulou, V.T., Theocharis, A.D., Ravazoula, P., Perimenis, P., Hjerpe, A., Karamanos, N.K., et al. Versican but not decorin accumulation is related to metastatic potential and neovascularization in testicular germ cell tumours. Histopathology 49 (2006), 582–593.
95. [95] Shen, X.H., Lin, W.R., Xu, M.D., Qi, P., Dong, L., Zhang, Q.Y., et al. Prognostic significance of Versican expression in gastric adenocarcinoma. Oncogenesis, 4, 2015, e178.
96. [96] Yang, M., Wang, L., Yang, J., Yang, G., Expression of Versican and its clinical significance in gastric carcinoma. Zhonghua Bing Li Xue Za Zhi 43 (2014), 473–477.
97. [97] Kim, N.S., Lee, H.H., Jung, C.K., Jeon, H.M., Versican expression in tumor epithelial cells is correlated with a good prognosis in gastric cancer. Anticancer Res. 34 (2014), 5613–5619.
98. [98] de Wit, M., Belt, E.J., Delis-van Diemen, P.M., Carvalho, B., Coupe, V.M., Stockmann, H.B., et al. Lumican and versican are associated with good outcome in stage II and III colon cancer. Ann. Surg. Oncol. 20 (2013), 348–359.
99. [99] Theocharis, A.D., Human colon adenocarcinoma is associated with specific post-translational modifications of versican and decorin. Biochim. Biophys. Acta 1588 (2002), 165–172.
100. [100] Du, W.W., Yang, B.B., Shatseva, T.A., Yang, B.L., Deng, Z., Shan, S.W., et al. Versican G3 promotes mouse mammary tumor cell growth, migration, and metastasis by influencing EGF receptor signaling. PLoS One, 5, 2010, 13828.
101. [101] Yee, A.J., Akens, M., Yang, B.L., Finkelstein, J., Zheng, P.S., Deng, Z., et al. The effect of versican G3 domain on local breast cancer invasiveness and bony metastasis. Breast Cancer Res., 9, 2007, 47.
102. [102] Dancevic, C.M., Fraser, F.W., Smith, A.D., Stupka, N., Ward, A.C., McCulloch, D.R., The biosynthesis and expression of A Disintegrin-like and Metalloproteinase domain with Thrombospondin-1 repeats -15: a novel versican-cleaving proteoglycanase. J. Biol. Chem. 288 (2013), 37267–37276.
103. [103] Read, J.T., Rahmani, M., Boroomand, S., Allahverdian, S., McManus, B.M., Rennie, P.S., Androgen receptor regulation of the versican gene through an androgen response element in the proximal promoter. J. Biol. Chem. 282 (2007), 31954–31963.
104. [104] Ristolainen, H., Kilpivaara, O., Kamper, P., Taskinen, M., Saarinen, S., Leppa, S., et al. Identification of homozygous deletion in ACAN and other candidate variants in familial classical Hodgkin lymphoma by exome sequencing. Br. J. Haematol. 170 (2015), 428–431.
105. [105] Nischalke, H.D., Lutz, P., Krämer, B., Söhne, J., Müller, T., Rosendahl, J., et al. A common polymorphism in the NCAN gene is associated with hepatocellular carcinoma in alcoholic liver disease. J. Hepatol. 61 (2014), 1073–1079.
106. [106] Oleszewski, M., Gutwein, P., von der Lieth, W., Rauch, U., Altevogt, P., Characterization of the L1-neurocan-binding site. Implications for L1-L1 homophilic binding. J. Biol. Chem. 275 (2000), 34478–34485.
107. [107] Faryna, M., Konermann, C., Aulmann, S., Bermejo, J.L., Brugger, M., Diederichs, S., et al. Genome-wide methylation screen in low-grade breast cancer identifies novel epigenetically altered genes as potential biomarkers for tumor diagnosis. FASEB J. 26 (2012), 4937–4950.
108. [108] Afratis, N., Gialeli, C., Nikitovic, D., Tsegenidis, T., Karousou, E., Theocharis, A.D., et al. Glycosaminoglycans: key players in cancer cell biology and treatment. FEBS J. 279 (2012), 1177–1197.
109. [109] Tammi, R.H., Kultti, A., Kosma, V.-M., Pirinen, R., Auvinen, P., Tammi, M.I., Hyaluronan in human tumors: pathobiological and prognostic messages from cell-associated and stromal hyaluronan. Sem. Cancer Biol. 18 (2008), 288–295.
110. [110] Turley, E.A., Wood, D.K., McCarthy, J.B., Carcinoma cell hyaluronan as a “portable” cancerized prometastatic microenvironment. Cancer Res. 76 (2016), 2507–2512.
111. [111] Chanmee, T., Ontong, P., Itano, N., Hyaluronan: a modulator of the tumor microenvironment. Cancer Lett. 375 (2016), 20–30.
112. [112] Schwertfeger, K.L., Cowman, M.K., Telmer, P.G., Turley, E.A., McCarthy, J.B., Hyaluronan, inflammation, and breast cancer progression. Front. Immunol., 6, 2015, 236.
113. [113] Wu, M., Cao, M., He, Y., Liu, Y., Yang, C., Du, Y., et al. A novel role of low molecular weight hyaluronan in breast cancer metastasis. FASEB J. 29 (2015), 1290–1298.
114. [114] Singleton, P.A., Hyaluronan regulation of endothelial barrier function in cancer. Adv. Cancer Res. 123 (2014), 191–209.
115. [115] Stern, R., Hyaluronan catabolism: a new metabolic pathway. Eur. J. Cell Biol. 83 (2004), 317–325.
116. [116] Adamia, S., Kriangkum, J., Belch, A.R., Pilarski, L.M., Aberrant posttranscriptional processing of hyaluronan synthase 1 in malignant transformation and tumor progression. Adv. Cancer Res. 123 (2014), 67–94.
117. [117] Ward, J.A., Huang, L., Guo, H., Ghatak, S., Toole, B.P., Perturbation of hyaluronan interactions inhibits malignant properties of glioma cells. Am. J. Pathol. 162 (2003), 1403–1409.
118. [118] Ghatak, S., Misra, S., Toole, B.P., Hyaluronan oligosaccharides inhibit anchorage-independent growth of tumor cells by suppressing the phosphoinositide 3-kinase/Akt cell survival pathway. J. Biol. Chem. 277 (2002), 38013–38020.
119. [119] Hosono, K., Nishida, Y., Knudson, W., Knudson, C.B., Naruse, T., Suzuki, Y., et al. Hyaluronan oligosaccharides inhibit tumorigenicity of osteosarcoma cell lines MG-63 and LM-8 in vitro and in vivo via perturbation of hyaluronan-rich pericellular matrix of the cells. Am. J. Pathol. 171 (2007), 274–286.
120. [120] Noordzij, M.A., van Steenbrugge, G.J., Verkaik, N.S., Schroder, F.H., van der Kwast, T.H., The prognostic value of CD44 isoforms in prostate cancer patients treated by radical prostatectomy. Clin. Cancer Res. 3 (1997), 805–815.
121. [121] Simpson, M.A., Wilson, C.M., McCarthy, J.B., Inhibition of prostate tumor cell hyaluronan synthesis impairs subcutaneous growth and vascularization in immunocompromised mice. Am. J. Pathol. 161 (2002), 849–857.
122. [122] Ghatak, S., Hascall, V.C., Markwald, R.R., Misra, S., Stromal hyaluronan interaction with epithelial CD44 variants promotes prostate cancer invasiveness by augmenting expression and function of hepatocyte growth factor and androgen receptor. J. Biol. Chem. 285 (2010), 19821–19832.
123. [123] Gao, A.C., Lou, W., Sleeman, J.P., Isaacs, J.T., Metastasis suppression by the standard CD44 isoform does not require the binding of prostate cancer cells to hyaluronate. Cancer Res. 58 (1998), 2350–2352.
124. [124] Brezillon, S., Pietraszek, K., Maquart, F.X., Wegrowski, Y., Lumican effects in the control of tumour progression and their links with metalloproteinases and integrins. FEBS J. 280 (2013), 2369–2381.
125. [125] Coulson-Thomas, V.J., Coulson-Thomas, Y.M., Gesteira, T.F., Andrade de Paula CA, Carneiro CRW, Ortiz V, Toma L, Kao WWY, Nader HB. Lumican expression, localization and antitumor activity in prostate cancer. Exp. Cell Res. 319 (2013), 967–981.
126. [126] Cappellesso, R., Millioni, R., Arrigoni, G., Simonato, F., Caroccia, B., Iori, E., et al. Lumican is overexpressed in lung adenocarcinoma pleural effusions. PLoS One, 10, 2015, e0126458.
127. [127] Brezillon, S., Venteo, L., Ramont, L., D'Onofrio, M.F., Perreau, C., Pluot, M., et al. Expression of lumican, a small leucine-rich proteoglycan with antitumour activity, in human malignant melanoma. Clin. Exp. Dermatol. 32 (2007), 405–416.
128. [128] Li, X., Truty, M.A., Kang, Y., Chopin-Laly, X., Zhang, R., Roife, D., et al. Extracellular lumican inhibits pancreatic cancer cell growth and is associated with prolonged survival after surgery. Clin. Cancer Res. 20 (2014), 6529–6540.
129. [129] Troup, S., Njue, C., Kliewer, E.V., Parisien, M., Roskelley, C., Chakravarti, S., et al. Reduced expression of the small leucine-rich proteoglycans, lumican, and decorin is associated with poor outcome in node-negative invasive breast cancer. Clin. Cancer Res. 9 (2003), 207–214.
130. [130] Wu, J., Liu, Z., Shao, C., Gong, Y., Hernando, E., Lee, P., et al. HMGA2 overexpression-induced ovarian surface epithelial transformation is mediated through regulation of EMT genes. Cancer Res. 71 (2011), 349–359.
131. [131] Gustavsson, H., Jennbacken, K., Welen, K., Damber, J.E., Altered expression of genes regulating angiogenesis in experimental androgen-independent prostate cancer. Prostate 68 (2008), 161–170.
132. [132] Kuno, K., Kanada, N., Nakashima, E., Fujiki, F., Ichimura, F., Matsushima, K., Molecular cloning of a gene encoding a new type of metalloproteinase-disintegrin family protein with thrombospondin motifs as an inflammation associated gene. J. Biol. Chem. 272 (1997), 556–562.
133. [133] Rocks, N., Paulissen, G., Quesada-Calvo, F., Munaut, C., Gonzalez, M.L., Gueders, M., et al. ADAMTS-1 metalloproteinase promotes tumor development through the induction of a stromal reaction in vivo. Cancer Res. 68 (2008), 9541–9550.
134. [134] Freitas, V.M., do Amaral, J.B., Silva, T.A., Santos, E.S., Mangone, F.R., Pinheiro Jde, J., et al. Decreased expression of ADAMTS-1 in human breast tumors stimulates migration and invasion. Mol. Cancer, 12, 2013, 2.
135. [135] Gustavsson, H., Wang, W., Jennbacken, K., Welen, K., Damber, J.E., ADAMTS1, a putative anti-angiogenic factor, is decreased in human prostate cancer. BJU Int. 104 (2009), 1786–1790.
136. [136] Le Bras, G.F., Taylor, C., Koumangoye, R.B., Revetta, F., Loomans, H.A., Andl, C.D., TGFβ loss activates ADAMTS-1-mediated EGF-dependent invasion in a model of esophageal cell invasion. Exp. Cell Res. 330 (2015), 29–42.
137. [137] Masui, T., Hosotani, R., Tsuji, S., Miyamoto, Y., Yasuda, S., Ida, J., et al. Expression of METH-1 and METH-2 in pancreatic cancer. Clin. Cancer Res. 7 (2001), 3437–3443.
138. [138] Turner, S.L., Mangnall, D., Bird, N.C., Bunning, R.A., Blair-Zajdel, M.E., Expression of ADAMTS-1, ADAMTS-4, ADAMTS-5 and TIMP3 by hepatocellular carcinoma cell lines. Int. J. Oncol. 41 (2012), 1043–1049.
139. [139] Fu, Y., Nagy, J.A., Brown, L.F., Shih, S.C., Johnson, P.Y., Chan, C.K., et al. Proteolytic cleavage of versican and involvement of ADAMTS-1 in VEGF-A/VPF-induced pathological angiogenesis. J. Histochem Cytochem 59 (2011), 463–473.
140. [140] Liu, Y.J., Xu, Y., Yu, Q., Full-length ADAMTS-1 and the ADAMTS-1 fragments display pro- and antimetastatic activity, respectively. Oncogene 25 (2006), 2452–2467.
141. [141] Wang, W., Lee, S., Steiglitz, B., Scott, I., Lebares, C., Allen, M., et al. Transforming growth factor-beta induces secretion of activated ADAMTS-2. A procollagen III N-proteinase. J. Biol. Chem. 278 (2003), 19549–19557.
142. [142] Dubail, J., Kesteloot, F., Deroanne, C., Motte, P., Lambert, V., Rakic, J.M., et al. ADAMTS-2 functions as anti-angiogenic and anti-tumoral molecule independently of its catalytic activity. Cell Mol. Life Sci. 67 (2010), 4213–4232.
143. [143] Rao, N., Ke, Z., Liu, H., Ho, C.J., Kumar, S., Xiang, W., et al. ADAMTS4 and its proteolytic fragments differentially affect melanoma growth and angiogenesis in mice. Int. J. Cancer 133 (2013), 294–306.
144. [144] Nakada, M., Miyamori, H., Kita, D., Takahashi, T., Yamashita, J., Sato, H., et al. Human glioblastomas overexpress ADAMTS-5 that degrades brevican. Acta Neuropathol. 110 (2005), 239–246.
145. [145] Matthews, R.T., Gary, S.C., Zerillo, C., Pratta, M., Solomon, K., Arner, E.C., et al. Brain-enriched hyaluronan binding (BEHAB)/brevican cleavage in a glioma cell line is mediated by a disintegrin and metalloproteinase with thrombospondin motifs (ADAMTS) family member. J. Biol. Chem. 275 (2000), 22695–22703.
146. [146] Viapiano, M.S., Hockfield, S., Matthews, R.T., BEHAB/brevican requires ADAMTS-mediated proteolytic cleavage to promote glioma invasion. J. Neurooncol. 88 (2008), 261–272.
147. [147] Hsu, Y.P., Staton, C.A., Cross, N., Buttle, D.J., Anti-angiogenic properties of ADAMTS-4 in vitro. Int. J. Exp. Pathol. 93 (2012), 70–77.
148. [148] Luque, A., Carpizo, D.R., Iruela-Arispe, M.L., ADAMTS1/METH1 inhibits endothelial cell proliferation by direct binding and sequestration of VEGF165. J. Biol. Chem. 278 (2003), 23656–23665.
149. [149] Kumar, S., Rao, N., Ge, R., Emerging roles of ADAMTSs in angiogenesis and cancer. Cancers (Basel) 4 (2012), 1252–1299.
150. [150] Kim, Y.H., Lee, H.C., Kim, S.Y., Yeom, Y.I., Ryu, K.J., Min, B.H., et al. Epigenomic analysis of aberrantly methylated genes in colorectal cancer identifies genes commonly affected by epigenetic alterations. Ann. Surg. Oncol. 18 (2011), 2338–2347.
151. [151] Porter, S., Scott, S.D., Sassoon, E.M., Williams, M.R., Jones, J.L., Girling, A.C., et al. Dysregulated expression of adamalysin-thrombospondin genes in human breast carcinoma. Clin. Cancer Res. 10 (2004), 2429–2440.
152. [152] Kumar, S., Sharghi-Namini, S., Rao, N., Ge, R., ADAMTS5 functions as an anti-angiogenic and anti-tumorigenic protein independent of its proteoglycanase activity. Am. J. Pathol. 181 (2012), 1056–1068.
153. [153] Filou, S., Stylianou, M., Triantaphyllidou, I.E., Papadas, T., Mastronikolis, N.S., Goumas, P.D., et al. Expression and distribution of aggrecanases in human larynx: ADAMTS-5/aggrecanase-2 is the main aggrecanase in laryngeal carcinoma. Biochimie 95 (2013), 725–734.
154. [154] Choi, G.C., Li, J., Wang, Y., Li, L., Zhong, L., Ma, B., et al. The metalloprotease ADAMTS8 displays anti-tumor properties through antagonizing EGFR-MEK-ERK signaling and is silenced in carcinomas by CpG methylation. Mol. Cancer Res. 12 (2014), 228–238.
155. [155] Dunn, J.R., Reed, J.E., du Plessis, D.G., Shaw, E.J., Reeves, P., Gee, A.L., et al. Expression of ADAMTS-8, a secreted protease with antiangiogenic properties, is downregulated in brain tumours. Br. J. Cancer 94 (2006), 1186–1193.
156. [156] Lo, P.H., Lung, H.L., Cheung, A.K., Apte, S.S., Chan, K.W., Kwong, F.M., et al. Extracellular protease ADAMTS9 suppresses esophageal and nasopharyngeal carcinoma tumor formation by inhibiting angiogenesis. Cancer Res. 70 (2010), 5567–5576.
157. [157] Lung, H.L., Lo, P.H., Xie, D., Apte, S.S., Cheung, A.K., Cheng, Y., et al. Characterization of a novel epigenetically-silenced, growth-suppressive gene, ADAMTS9, and its association with lymph node metastases in nasopharyngeal carcinoma. Int. J. Cancer 123 (2008), 401–408.
158. [158] Clark, M.E., Kelner, G.S., Turbeville, L.A., Boyer, A., Arden, K.C., Maki, R.A., ADAMTS9, a novel member of the ADAM-TS/metallospondin gene family. Genomics 67 (2000), 343–350.
159. [159] El Hour, M., Moncada-Pazos, A., Blacher, S., Masset, A., Cal, S., Berndt, S., et al. Higher sensitivity of Adamts12-deficient mice to tumor growth and angiogenesis. Oncogene 29 (2010), 3025–3032.
160. [160] Llamazares, M., Obaya, A.J., Moncada-Pazos, A., Heljasvaara, R., Espada, J., Lopez-Otin, C., et al. The ADAMTS12 metalloproteinase exhibits anti-tumorigenic properties through modulation of the Ras-dependent ERK signalling pathway. J. Cell Sci. 120 (2007), 3544–3552.
161. [161] Fontanil, T., Rua, S., Llamazares, M., Moncada-Pazos, A., Quiros, P.M., Garcia-Suarez, O., et al. Interaction between the ADAMTS-12 metalloprotease and fibulin-2 induces tumor-suppressive effects in breast cancer cells. Oncotarget 5 (2014), 1253–1264.
162. [162] Moncada-Pazos, A., Obaya, A.J., Fraga, M.F., Viloria, C.G., Capella, G., Gausachs, M., et al. The ADAMTS12 metalloprotease gene is epigenetically silenced in tumor cells and transcriptionally activated in the stroma during progression of colon cancer. J. Cell Sci. 122 (2009), 2906–2913.
163. [163] Wang, D., Zhu, T., Zhang, F., He, C., Expression of ADAMTS12 in colorectal cancer-associated stroma prevents cancer development and is a good prognostic indicator of colorectal cancer. Dig. Dis. Sci. 56 (2011), 3281–3287.
164. [164] Porter, S., Span, P.N., Sweep, F.C., Tjan-Heijnen, V.C., Pennington, C.J., Pedersen, T.X., et al. ADAMTS8 and ADAMTS15 expression predicts survival in human breast carcinoma. Int. J. Cancer 118 (2006), 1241–1247.
165. [165] Viloria, C.G., Obaya, A.J., Moncada-Pazos, A., Llamazares, M., Astudillo, A., Capella, G., et al. Genetic inactivation of ADAMTS15 metalloprotease in human colorectal cancer. Cancer Res. 69 (2009), 4926–4934.
166. [166] Kelwick, R., Wagstaff, L., Decock, J., Roghi, C., Cooley, L.S., Robinson, S.D., et al. Metalloproteinase-dependent and -independent processes contribute to inhibition of breast cancer cell migration, angiogenesis and liver metastasis by a disintegrin and metalloproteinase with thrombospondin motifs-15. Int. J. Cancer 136 (2014), 14–26.
167. [167] Sjoblom, T., Jones, S., Wood, L.D., Parsons, D.W., Lin, J., Barber, T.D., et al. The consensus coding sequences of human breast and colorectal cancers. Science 314 (2006), 268–274.
168. [168] Jones, S., Zhang, X., Parsons, D.W., Lin, J.C., Leary, R.J., Angenendt, P., et al. Core signaling pathways in human pancreatic cancers revealed by global genomic analyses. Science 321 (2008), 1801–1806.
169. [169] Chuu, C.P., Kokontis, J.M., Hiipakka, R.A., Fukuchi, J., Lin, H.P., Lin, C.Y., et al. Androgens as therapy for androgen receptor-positive castration-resistant prostate cancer. J. Biomed. Sci., 18, 2011, 63.
170. [170] Li, Z., Zhang, W., Shao, Y., Zhang, C., Wu, Q., Yang, H., et al. High-resolution melting analysis of ADAMTS18 methylation levels in gastric, colorectal and pancreatic cancers. Med. Oncol. 27 (2010), 998–1004.
171. [171] Wei, X., Prickett, T.D., Viloria, C.G., Molinolo, A., Lin, J.C., Cardenas-Navia, I., et al. Mutational and functional analysis reveals ADAMTS18 metalloproteinase as a novel driver in melanoma. Mol. Cancer Res. 8 (2010), 1513–1525.
172. [172] Jin, H., Wang, X., Ying, J., Wong, A.H., Li, H., Lee, K.Y., et al. Epigenetic identification of ADAMTS18 as a novel 16q23.1 tumor suppressor frequently silenced in esophageal, nasopharyngeal and multiple other carcinomas. Oncogene 26 (2007), 7490–7498.
173. [173] Xie, Y., Gou, Q., Xie, K., Wang, Z., Wang, Y., Zheng, H., ADAMTS6 suppresses tumor progression via the ERK signaling pathway and serves as a prognostic marker in human breast cancer. Oncotarget, 2016, 10.18632/oncotarget.11341 Epub [Aug 17].
174. [174] Suzuki, K., Suzuki, I., Leodolter, A., Alonso, S., Horiuchi, S., Yamashita, K., et al. Global DNA demethylation in gastrointestinal cancer is age dependent and precedes genomic damage. Cancer Cell 9 (2006), 199–207.
175. [175] Alonso, S., Dai, Y., Yamashita, K., Horiuchi, S., Dai, T., Matsunaga, A., et al. Methylation of MGMT and ADAMTS14 in normal colon mucosa: biomarkers of a field defect for cancerization preferentially targeting elder African-Americans. Oncotarget 6 (2015), 3420–3431.
176. [176] Su, S.C., Hsieh, M.J., Liu, Y.F., Chou, Y.E., Lin, C.W., Yang, S.F., ADAMTS14 gene polymorphism and environmental risk in the development of oral cancer. PLoS One, 11, 2016, e0159585.
177. [177] Filou, S., Korpetinou, A., Kyriakopoulou, D., Bounias, D., Stavropoulos, M., Ravazoula, P., et al. ADAMTS expression in colorectal cancer. PLoS One, 10, 2015, e0121209.
178. [178] Sakamoto, N., Oue, N., Noguchi, T., Sentani, K., Anami, K., Sanada, Y., et al. Serial analysis of gene expression of esophageal squamous cell carcinoma: ADAMTS16 is upregulated in esophageal squamous cell carcinoma. Cancer Sci. 101 (2010), 1038–1044.
179. [179] Roy, R., Zurakowski, D., Wischhusen, J., Frauenhoffer, C., Hooshmand, S., Kulke, M., et al. Urinary TIMP-1 and MMP-2 levels detect the presence of pancreatic malignancies. Br. J. Cancer 111 (2014), 1772–1779.
180. [180] Mohammed, M.A., Seleim, M.F., Abdalla, M.S., Sharada, H.M., Abdel Wahab, A.H., Urinary high molecular weight matrix metalloproteinases as non-invasive biomarker for detection of bladder cancer. BMC Urol., 13, 2013, 25.
181. [181] Hanahan, D., Weinberg, R.A., Hallmarks of cancer: the next generation. Cell 144 (2011), 646–674.
182. [182] Wight, T.N., Kang, I., Merrilees, M.J., Versican and the control of inflammation. Matrix Biol. 35 (2014), 152–161.
183. [183] Heldin, P., Karousou, E., Bernert, B., Porsch, H., Nishitsuka, K., Skandalis, S.S., Importance of hyaluronan-CD44 interactions in inflammation and tumorigenesis. Connect. Tissue Res. 49 (2008), 215–218.
184. [184] Tolg, C., McCarthy, J.B., Yazdani, A., Turley, E.A., Hyaluronan and RHAMM in wound repair and the “cancerization” of stromal tissues. Biomed. Res. Int., 2014, 2014, 103923.
185. [185] Mancek-Keber, M., Inflammation-mediating proteases: structure, function in (patho) physiology and inhibition. Protein Pept. Lett. 21 (2014), 1209–1229.
186. [186] Cal, S., Lopez-Otin, C., ADAMTS proteases and cancer. Matrix Biol. 44–46 (2015), 77–85.
187. [187] Said, N., Sanchez-Carbayo, M., Smith, S.C., Theodorescu, D., RhoGDI2 suppresses lung metastasis in mice by reducing tumor versican expression and macrophage infiltration. J. Clin. Investig. 122 (2012), 1503–1518.
188. [188] Mladenovic, Z., Saurel, A.S., Berenbaum, F., Jacques, C., Potential role of hyaluronic acid on bone in osteoarthritis: matrix metalloproteinases, aggrecanases, and RANKL expression are partially prevented by hyaluronic acid in interleukin 1-stimulated osteoblasts. J. Rheumatol. 41 (2014), 945–954.
189. [189] Ariyoshi, W., Takahashi, N., Hida, D., Knudson, C.B., Knudson, W., Mechanisms involved in enhancement of the expression and function of aggrecanases by hyaluronan oligosaccharides. Arthritis Rheum. 64 (2012), 187–197.
190. [190] Oller, J., Alfranca, A., Mendez-Barbero, N., Villahoz, S., Lozano-Vidal, N., Martin-Alonso, M., et al. C/EBPbeta and nuclear factor of activated T cells differentially regulate Adamts-1 induction by stimuli associated with vascular remodeling. Mol. Cell Biol. 35 (2015), 3409–3422.
191. [191] Lemarchant, S., Dunghana, H., Pomeshchik, Y., Leinonen, H., Kolosowska, N., Korhonen, P., et al. Anti-inflammatory effects of ADAMTS-4 in a mouse model of ischemic stroke. Glia 64 (2016), 1492–1507.
192. [192] Zhang, Y., Lin, J., Wei, F., The function and roles of ADAMTS-7 in inflammatory diseases. Mediat. Inflamm., 2015, 2015, 801546.
193. [193] Paulissen, G., El Hour, M., Rocks, N., Gueders, M.M., Bureau, F., Foidart, J.M., et al. Control of allergen-induced inflammation and hyperresponsiveness by the metalloproteinase ADAMTS-12. J. Immunol. 189 (2012), 4135–4143.
194. [194] Cai, P., Luo, H., Xu, H., Zhu, X., Xu, W., Dai, Y., et al. Recombinant ADAMTS 13 attenuates brain injury after intracerebral hemorrhage. Stroke 46 (2015), 2647–2653.
195. [195] Alper, M., Kockar, F., IL-6 upregulates a disintegrin and metalloproteinase with thrombospondin motifs 2 (ADAMTS-2) in human osteosarcoma cells mediated by JNK pathway. Mol. Cell Biochem. 393 (2014), 165–175.